News
New ALT Biomarker Enhances Prognostic Accuracy in Pancreatic Neuroendocrine Tumors
Pancreatic neuroendocrine tumors (PanNETs) can have a variety of behaviors. Some stay slow-growing for years, while others take a sudden, aggressive turn, even when they’re
Belzutifan Approved for Pheo Para
In a breakthrough for those with advanced pheochromocytoma and paraganglioma (Pheo/Para), the U.S. Food and Drug Administration (FDA) has approved WELIREG® (belzutifan) as a treatment
Driving Progress in NET Research: An Interview with Dr. Anna Greene
In a recent interview with CancerNetwork®, Dr. Anna Greene, Director of Research at the Neuroendocrine Tumor Research Foundation (NETRF), spotlighted the foundation’s leadership as the
CAR T-cell Clinical Trial Expands to Fourth Site
Patient enrollment has begun at a fourth site for the world’s first CAR T-cell therapy clinical trial for neuroendocrine cancer. Winship Cancer Center at Emory
Unlocking Personalized Treatment for Lung Neuroendocrine Tumors
Lung neuroendocrine tumors (lung NETs) make up 20-30% of all neuroendocrine cancers, yet their diversity and complexity have long puzzled researchers and clinicians. Now, thanks
New Clinical Trial to Evaluate Plixorafenib for BRAF V600E-mutated Neuroendocrine Carcinoma
A new global clinical trial is evaluating the investigational drug FORE8394 (plixorafenib) for treatment of neuroendocrine carcinomas with BRAF V600E-mutations. The phase 2 study aims
New Trial to Evaluate Combination of Fulvestrant and 177Lu-DOTATATE in Advanced Pancreatic Neuroendocrine Tumors
A new clinical trial at the University of Chicago Medicine is evaluating the combination of 177Lu-DOTATATE with fulvestrant in patients with advanced pancreatic neuroendocrine tumors
Understanding Ovarian Neuroendocrine Tumors: New Research Sheds Light on Diagnosis and Treatment
Neuroendocrine tumors (NETs) are complex cancers that can originate in various organs, including the ovaries. While primary ovarian NETs (PON) are uncommon, distinguishing them from
A Very Personal Perspective on the Value of Research
As the Director of Research at the Neuroendocrine Tumor Research Foundation (NETRF), I’ve dedicated my career to advancing science that gives patients and families more
A New Treatment Option for NET Patients
The U.S. Food and Drug Administration (FDA) has approved cabozantinib for the treatment of previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors